Clinical Trials Browser

Phase 3 × Interventional × Afatinib × Clear all

NCT01856478 2026-01-12

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3 Completed

340 enrolled 23 charts

Head and Neck Neoplasms

NCT06759857 2025-01-06

FHND9041

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

NCT06486142 2024-07-03

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01427478 2021-06-01

BIBW2992ORL

Phase 3 Completed

Squamous Cell Carcinoma of Head and Neck

NCT01953913 2019-08-12

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 3 Completed

542 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01125566 2019-07-18

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Phase 3 Completed

508 enrolled 13 charts

Breast Neoplasms

NCT01523587 2019-02-15

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Phase 3 Completed

795 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Phase 3 Completed

364 enrolled 28 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 1 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT01345682 2018-02-15

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3 Completed

483 enrolled 21 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01345669 2017-12-07

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3 Terminated

617 enrolled 13 charts

Head and Neck Neoplasms

NCT02044380 2017-03-31

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Phase 3 Completed

14 enrolled 6 charts

Carcinoma, Non-Small-Cell Lung

NCT00656136 2016-07-26

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Phase 3 Completed

585 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung